þ T cells are key effectors of the immune response against human cytomegalovirus (HCMV). A number of HCMV-derived CD8 þ T cell epitopes are known. Using epitope prediction and subsequent testing for interferon-g responses by the ELISPOT assay, we identified an optimal human leukocyte antigen (HLA)-A*0201-restricted CD8 þ T cell epitope derived from the major immediate early 1 (IE-1) gene product. As many as one-third of HLA-A*0201-positive, HCMV-seropositive donors make responses to this peptide (residues 316-324 [VLEETSVML]), which can exceed responses against a published immunodominant pp65 epitope (residues 495-503 [NLVPMVATV]). Major histocompatibility complex peptide tetramer staining facilitated detailed phenotypic analyses and revealed populations that resemble terminally differentiated effector cells (CD57 þ and CD28 2 ), with considerable restriction in T cell receptor b-chain variable region use. The results confirm that, although pp65 is a major target for CD8 þ T cells, the IE-1 protein may itself stimulate comparable responses in some persons.
Human cytomegalovirus (HCMV) is a widespread betaherpesvirus that infects 60%-90% of the population worldwide. Primary infection is largely asymptomatic and is followed by a period of lifelong persistence in several types of cells, including those of the myeloid lineage. In immunocompromised hosts, such as transplant recipients and patients with advanced human immunodeficiency virus infection, HCMV reactivation can be the cause of life-threatening disease [1] . Studies in animal models (murine CMV) and data derived from immunocompromised humans have suggested that the cellular immune response plays a key role in control of viral replication and subsequent disease [2] [3] [4] . Cytotoxic T lymphocytes (CTL) have been implicated as the principal mediators of protection against HCMV. T lymphocytes recognize HCMV antigens when the viral peptides are presented by self major histocompatibility complex molecules at the surfaces of infected cells. The CD8 þ T cell response to HCMV appears to be very focused, with identification of only a few proteins as immunodominant targets. Two proteins have been of particular interest: the 72-kDa transactivator protein known as the "HCMV major immediate early 1 gene product" and the structural phosphoprotein pp65.
The CD8
þ T cell response directed against HCMV proteins was originally investigated using conventional limiting dilution methods by restimulation of T cell responses with the laboratoryadapted HCMV strain AD169 and vaccinia viruses expressing HCMV proteins [5] [6] [7] [8] . More recent studies have used peptideinducible intracellular interferon (IFN)-g production [9, 10] and staining with HLA peptide tetrameric complexes to reveal the frequency of antigen-specific cells in a T cell population [11] [12] [13] . A comparison of these technologies has shown that the earlier studies largely underestimated the magnitude of HCMVspecific CD8 þ T cell responses in seropositive donors. In particular, CD8
þ T cells against the immediate early 1 (IE-1) gene product were thought to be much lower in frequency than those against pp65 [7] , which has been regarded as the immunodominant HCMV antigen [7, 8] . These more recent approaches have shown that frequencies of CD8 þ T cells specific for either protein can represent several percent of the total CD8 þ T cell subset, and responses against single IE-1 epitopes can, in some donors, exceed those of pp65-specific CD8 þ T cells [9, 10, 14] . Another study, which used limiting dilution analysis and canarypox recombinant viruses expressing different HCMV proteins, has supported these findings [15] . Together these data have led to a reevaluation of our understanding of HCMV-specific T cell responses.
A number of HCMV epitopes have been discovered, both from IE-1 and pp65 proteins [16] , and these may allow design of a peptide-based vaccine [17] . The 1990s also witnessed advances in understanding of antigen presentation and identification of major histocompatibility complex binding motifs for different major histocompatibility complex molecules [18] . Using peptide-binding computer algorithms in combination with the ELISPOT assay to measure IFN-g production (in response to in-cubation of cells with peptide), we aimed to identify novel IE-1 protein-derived immunogenic peptides. This was followed by detailed analysis of the phenotype and clonality of T cell populations specific for the discovered antigenic determinants.
Subjects, Materials, and Methods
Subjects. Peripheral blood (20-50 mL) was collected from healthy adult volunteers by venipuncture into heparinized Vacutainers (Becton Dickinson). A latex agglutination kit (CMVScan; Becton Dickinson) was used to determine HCMV serostatus, using plasma samples. Blood (5 mL) collected in EDTA Vacutainers was used for HLA class I tissue typing, which was done by the local blood transfusion service. Eighteen HLA-A*0201-positive, HCMVseropositive donors were studied. Five HLA-A*0201-negative, HCMV-seropositive donors and 3 HLA-A*0201-positive, HCMVseronegative donors were selected as control subjects.
Isolation of mononuclear cells. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples by Ficoll-Paque density gradient centrifugation (Axis Shield), washed twice in RPMI 1640 medium (Life Technologies), and then resuspended in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 100 U/mL penicillin-streptomycin (Sigma). Cells were used immediately or cryopreserved.
Peptides. All peptides were synthesized commercially by Invitrogen/Research Genetics. Eight putative HLA-A*0201-binding nonameric peptides derived from the IE-1 protein sequence (HCMV strain AD169) were synthesized and used in this study: VLAELVRQI (residues 81-89), ILDEERDKV (residues 256-264), TMYGGISLL (residues 297-305), SLLSEFCRV (residues 303-311), LLSEF-CRVL (residues 304-312), YVLEETSVM (residues 315-323), VLE-ETSVML (residues 316-324), and ILGADPLRV (residues 355-363). The pp65-derived HLA*0201-restricted peptide NLVPMVATV was also synthesized. Reference to each peptide is made by the first 3 aa (e.g., VLAELVRQI is designated "VLA"). These putative HLA-A*0201-binding peptides were selected using the epitope prediction programs available at http://www-bimas.dcrt.nih.gov/ molbio/hla_bind/index.html and http://syfpeithi.bmi-heidelberg .com/Scripts/MHCServer.dll/EpPredict.htm.
ELISPOT for IFN-g. Ninety-six-well polyvinylidene difluoride-backed plates (Millipore) were coated with 15 mg/mL anti-IFN-g monoclonal antibody (MAb) 1-DIK (Mabtech) at room temperature for 3 h. After wells were washed with filtered RPMI 1640 medium, PBMC were added to duplicate wells at different concentrations (2 £ 10 5 , 1 £ 10 5 , 5 £ 10 4 , and 2:5 £ 10 4 cells/well) in the presence of 2 mM peptide. Dimethyl sulfoxide and phytohemagglutinin were added to negative and positive control wells, respectively. After incubation for 16 h at 37 C in 5% CO 2 , the cells were discarded, and wells were washed with PBS containing 0.05% Tween (Sigma). This was followed by incubation with 1 mg/mL biotinylated anti-IFN-g MAb 7-B6-1-biotin (Mabtech) for 3 h at room temperature. Wells were washed again and then incubated with streptavidin-conjugated alkaline phosphatase (Mabtech) for another 2 h. Individual cytokine-producing cells were identified as dark spots after a 30-min reaction with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium by means of an alkaline phosphatase-conjugate substrate kit (Bio-Rad). Spots were counted and expressed as the percentage of PBMC that produced IFN-g in response to peptide.
Generation of HLA peptide tetramers. HLA-A*0201 tetramers incorporating pp65 residues 495-503 (NLVPMVATV) and IE-1 residues 316-324 (VLEETSVML) were synthesized by use of standard methods [11, 12] . Briefly, class I heavy chains (modified by substitution of the transmembrane and cytoplasmic domains by a BirA target sequence) and b 2 -microglobulin were expressed in BL21(DE3)pLysS and lA90 strains of Escherichia coli, respectively, and proteins were purified as inclusion bodies solubilized in 8 M urea. Heavy chain and b 2 -microglobulin were refolded around the appropriate peptide for 48 h at 4 C. The sample was then concentrated and biotinylated overnight at room temperature by use of the enzyme BirA. Refolded complexes were purified by fast protein liquid chromatography with gel filtration and ion exchange columns (Amersham Pharmacia). Tetrameric complexes were made by addition of phycoerythrin-conjugated streptavidin (Molecular Probes) in a molar ratio of 1:4 to the biotinylated monomer over the course of 3-4 days.
Cell staining with antibodies and tetramers. PBMC (2 £ 10 5 ) were incubated with VLE or NLV tetramer at 37 C for 30 min. After being washed with PBS containing 2% fetal calf serum, cells were incubated with saturating concentrations of tricolor-conjugated anti-CD8 MAb (CALTAG Laboratories) for another 30 min on ice. Cells were washed and then fixed in PBS containing 2% formaldehyde and 2% fetal calf serum. Samples were analyzed on a Coulter XL flow cytometer, and those data were analyzed using WinMDI (version 2.8; Scripps Research Institute) software. Tetramer staining was also done at 4 C and 20 C, but no great differences (,10%) in tetramer staining were observed. However, the mean fluorescence of tetramer staining was higher at 37 C, so this temperature was selected for use.
Phenotypic analyses were done by 3-color immunofluorescence. After tetramer staining, cells were incubated with tricolor-conjugated anti-CD8 MAb and an MAb from a panel of MAbs directly conjugated to fluorescein isothiocyanate (FITC) for 20 min on ice. The panel included anti-CD57 (Serotec); anti-CD45RA, anti-CD45RO, anti-CD28, anti-CD27, anti-CCR7, anti-HLA-DR, anti-CD38, and anti-CD69 (all Pharmingen); and anti-perforin (Alexis). For intracellular staining, cells were stained with tetramer and antibodies, washed, and then fixed and permeabilized (reagents from Immunotech). Cells were then incubated with anti-perforin MAb for 1 h and washed again before analysis.
T cell receptor b-chain variable region (TCRBV) use was determined by indirect immunofluorescence. After tetramer staining at 37 C, cells were incubated on ice with saturating amounts of an MAb from a panel of mouse anti-human TCRBV MAbs (BV1, BV2, BV3, BV4, BV5.1, BV5.2, BV5.3, BV6.7, BV7, BV8, BV9, BV11, BV12, BV13.1, BV13.6, BV14, BV16, BV17, BV18, BV20, BV21.3, BV22, and BV23; Immunotech). Cells were washed and then incubated with a goat anti-mouse IgG-FITC MAb (Dako). Consequently, incubation with the mouse anti-human CD8-tricolor MAb (CALTAG Laboratories) was done last. Mouse serum (Serotec) was used to block binding of anti-mouse IgG-FITC MAb to the mouse anti-human CD8-tricolor MAb. Compensation and isotype controls were carried out simultaneously. PBMC of HCMV-seronegative or HLA-A*0201-negative donors were also stained with tetramers, as a further control. Tetramer staining did not exceed background levels (,0.05% of CD8 þ T cells). DNA sequencing of tetramer-selected TCRBVs. PBMC (5 £ 10 7 to 10 £ 10 7 ) were stained with tetramer, as described earlier, washed, and incubated with anti-phycoerythrin microbeads (Miltenyi Biotech) for 20 min on ice. Cells were washed again and subjected to magnetic separation. All fractions were counterstained with anti-human CD8-tricolor MAb and washed. Analysis by flow cytometry was done with a small aliquot of cells from each fraction. Positively selected fractions were made up of .98% tetramer-staining CD8 þ T cells. RNA from positively selected cells was extracted with Trizol (Life Technologies) and then reverse transcribed with an oligo-dT primer with use of Superscript II reverse transcriptase (Life Technologies) in a 20-mL reaction containing 50 mM TrisHCl (pH 8.3), 75 mM KCl, 10 mM dithiothreitol, and 0.5 mM each dNTP, according to the manufacturer's instructions. cDNA was then amplified with a panel of primers specific for TCRBV families 1-24 [19] for 40 cycles of 94 C for 30 s, 60 C for 30 s, and 72 C for 40 s, with use of AmpliTaq DNA polymerase (Applied Biosystems). PCR products were visualized with ethidium bromide staining, and reactions identified as positive were digested with Not I and Sal I restriction enzymes. Digests were purified by gel extraction (Qiagen) and then cloned into an M13 phagescript l vector (Stratagene) with XL-1 Blue MRF 0 cells (Stratagene) as the host strain of E. coli. Recombinant plaques were identified by blue-white color selection and sequenced with a Bigdye Terminator cycle sequencing kit (Applied Biosystems).
Single-cell sorting and cytotoxicity assays. PBMC were stained with VLE tetramer and anti-human CD8-tricolor MAb and then washed before being sorted with a FACS Vantage cell sorter (Becton Dickinson). Single CD8 þ tetramer-positive cells were dropped into 96-well plates containing 200 mL of cloning mix (10 6 allogeneic PBMC and 10 5 Epstein-Barr virus-transformed autologous lymphoblastoid cell lines [LCLs]/mL) in RPMI 1640 medium supplemented with 10% fetal calf serum and 1% AB human serum, 50 U/mL interleukin-2, and 5 ng/mL interleukin-7. After 14 days, growing microcultures were expanded to 2-mL cultures and tested in standard 51 Cr release assays. Autologous LCLs and fibroblasts were used as target cells. LCLs were labeled with 51 Cr for 1 h before being pulsed with 1 mg/mL peptide for 1 h. Fibroblasts were infected with the AD169 strain of HCMV at an MOI of 5:1 overnight and pulsed the next day with 51 Cr for 2 h. For selected assays, fibroblasts were pretreated with 100 U/mL IFN-g for 48 h, washed, and infected with virus. Targets were washed twice, counted, and then plated out at 2500 cells/well. T cells were added at various ratios of effector cells to target cells in triplicate. After a 5-h incubation at 37 C with 5% CO 2 , supernatants were harvested, and lysis was determined by use of a Gamma counter (Packard). Lysis values were calculated with the formula ðtest release 2 spontaneous releaseÞ=ðmaximal release 2 spontaneous releaseÞ.
Results
Screening for IFN-g responses to predicted IE-1 epitopes by the ELISPOT assay. Among 18 HLA-A*0201-positive HCMVseropositive donors studied, in 7 donors we detected significant IFN-g responses to 2 of 8 putative IE-1 epitopes: residues 315-323 (YVLEETSVM) and 316-324 (VLEETSVML). Six of 18 donors made responses to the VLE peptide, and 1 donor (017) made a response to YVL ( figure 1A and table 1 ). Because the initial batches of peptide were relatively crude, we repeated the ELISPOT assays, using peptides from a stock made on a higher scale of purification. The results confirmed that responses were specifically to these 2 peptides, with no cross-reactivity between donors. Further experiments (figure 1B) with the shorter, octameric peptide 316-323 (VLEETSVM) and with 317-325 (LEETSVMLA) revealed that the minimal epitope was indeed the nonameric peptide VLEETSVML (residues 316-324). The YVL peptide matched that identified previously by Retiere et al. [20] , except for a V!I substitution at position 2. Because donor 017's ELISPOT responses to YVL and YIL peptides were very comparable (data not shown), we concluded that this amino acid difference did not alter immunogenicity. In addition, we compared responses to the VLE peptide with responses to the pp65 epitope NLV and observed that 2 of 6 donors who made a VLE response did not show an NLV response on ELISPOT ( figure 1C ). The HCMV-seronegative donors and HCMV-seropositive, HLA-A*0201-negative donors included in our study did not make responses against any of the peptides.
HLA-A*0201 peptide tetramer staining in samples from donors who made ELISPOT responses to IE-1 peptides. The ELI-SPOT assay revealed a group of donors who made potent IFN-g responses to 2 IE-1-derived peptides. We then proceeded to construct an HLA-A*0201 tetramer incorporating the VLE peptide to stain PBMC and directly visualize the number of circulating CD8 þ T cells specific to this peptide. Results showed that the frequencies were very high, ranging from 0.1% to 4.25% of CD8 þ T cells (table 2) . Although the proportion of donors who responded to the VLE peptide was lower than the proportion of donors who responded the NLV peptide, the frequency of VLEspecific T cells among these donors was higher than that of NLVspecific CD8 þ T cells. The frequencies found with tetramer staining also exceeded the frequencies measured by ELISPOT, which was expected, because not all antigen-specific CD8 þ T cells are likely to function in such an in vitro test. A direct comparison of the 2 methods showed that the peptide-specific T cell frequencies measured by ELISPOT were 10%-50% of the frequency found by tetramer staining for the same peptide. This observation held true for responses against both pp65 and IE-1 peptides (data not shown). We also synthesized tetramers incorporating the YVL or YIL epitopes, but, unexpectedly, these did not stain either PBMC or a polyclonal CTL line, which lysed both YVL-and YIL-pulsed autologous Epstein-Barr virus-transformed B cell LCLs from donor 017 (data not shown).
Phenotypic analysis of IE-1 peptide-specific CD8 þ T cells and comparison with pp65 epitope-specific CD8 þ T cells. The innovation of HLA peptide tetramers has revolutionized the study of complex T cell populations. One application that tetramers have made possible is the ability to study the cell-surface phenotype of antigen-specific T cells ex vivo. Previous studies that ex-amined HCMV pp65 epitope-specific CD8 þ T cells have shown a polarization of pp65-specific CD8 þ T cells toward high CD57 expression and low levels of the costimulatory molecule CD28 [14] . This indicated that these populations were long-lived and highly differentiated. Furthermore, expression of the CD45RA isoform, often in combination with CD45RO, is also seen. Our results showed that CD8 þ T cells specific to both the novel IE-1 epitope (VLE) and the published pp65 epitope (NLV) have a very similar phenotype. We carried out phenotype analysis on samples from 5 donors that showed high VLE staining (table 3) and observed a consistent pattern of high CD57 expression, low levels of both CD28 and CCR7 (figure 2), high levels of intracellular perforin, and the absence of markers of T cell activation (HLA-DR, CD38, and CD69). There was more heterogeneity in CD27 and CD45RA/RO expression. VLE-specific cells in some donors (donors 006 and 014) had high levels of CD45RA and low levels of CD27 and CD45RO. In others (donors 004 and 015), the VLE-specific cells expressed some CD27 (15% and 40%, respectively) and appeared to be double-positive for CD45 isoforms (i.e., with intermediate levels of CD45RA and CD45RO). VLE-specific cells from donor 002 predominantly had low levels of CD45RA and high levels of CD45 RO, and 50% of the cells expressed CD27. This was almost identical to the phenotype of NLV-specific CD8 þ T cells from this donor ( figure 2C and 2D ).
TCRBV use of IE-1-specific CD8
þ T cells. To determine the level of TCRBV use of VLE-specific CD8 þ T cells, we stained PBMC with tetramer and a panel of anti-TCRBV MAbs and then made an analysis using flow cytometry. Five donors identified earlier were studied. We observed VLE tetramer/TCRBV MAb costaining in PBMC of 4 of 5 donors. Interestingly, the ex- pression of TCRBV alleles was very restricted (figure 3). In donor 002, it appeared that a single b chain (TCRBV4) was used; in donor 014, 2 TCR b chains (TCRBV5.1 and TCRBV14) were used; and in donor 004, at least 2 b chains were used, with 1 (TCRBV5.1) constituting . 90% of the antigen-specific CD8 þ T cells. In donor 015, at least 3 b chains were used, and 2 of these (TCRBV1 and TCRBV5.1) were identified by MAb staining. We found no costaining of any TCRBV MAb with tetramer in the case of donor 006. This was probably because the current panel of TCRBV MAbs covers only 50%-70% of the total T cell repertoire. We have also observed similar restriction in TCRBV use against the pp65 epitope NLV (table 4), with 1 TCRBV constituting . 60% of the response in each case.
We then studied the clonal nature of these populations by sequencing the junctional regions of purified tetramer-binding cells from 4 donors (table 4) and found extreme levels of restriction. Only 2 clonotypes (TCRBV5.1 and TCRBV14) were detected in the case of donor 014, and the same TCRBV5.1 clonotype identified in donor 014 was used by donors 004 and 015. The TCRBV4s used by donor 002 comprised a single transcript. This result demonstrates that IE-1 epitope-specific CD8 þ T cells are represented by .1 clone, as has been reported for pp65 epitope-specific CD8 þ T cells [21] . Functional analysis of VLE-specific CD8 þ T cell clones. We also generated T cell clones specific for the VLE epitope by use of flow cytometry to select tetramer-binding cells from PBMC of donors 002 and 014. The peptide specificity of these clones was confirmed in 51 Cr release assays with use of VLE peptide-loaded autologous LCLs as target cells ( figure 4A ). Subsequent TCRBV analysis (data not shown) confirmed the expression of TCRBV4 (donor 002) and either TCRBV5.1 or TCRBV14 (donor 014) on these T cell clones.
The same clones were tested for the ability to lyse virally infected cells by use of the AD169 strain of HCMV. The results showed that VLE-specific clones kill virally infected targets at relatively low levels, whereas NLV-specific clones killed such targets very efficiently. However, VLE-specific clones could lyse HCMV-infected target cells pretreated with IFN-g ( figure 4B ), as has been demonstrated by others [22] .
Discussion
In this study, we used epitope prediction to design potential HLA-A*0201-binding peptides from the HCMV IE-1 protein and demonstrated responses to 2 of 8 peptides tested by the ELI-SPOT assay for IFN-g. Other groups have used epitope prediction to identify CMV-specific CTL [23] , and these studies, when they are combined with functional assays, provide a rapid and efficient way of identifying novel epitopes. It has been argued elsewhere that IE-1-specific responses constitute a minority of the Table 3 . Phenotypic analyses of human cytomegalovirus peptide-specific CD8 þ T cells.
NOTE. Data are fraction of tetramer-binding cells expressing the given marker. NT, not tested; þþþ, . 75%; þþ, 40%-75%; þ , 20%-40%; þ /2 , 10%-20%; 2 , , 10%. Figure 2 . HLA peptide tetramer staining and cell-surface phenotype of VLE-specific CD8 þ T cells, determined by tricolor immunofluorescence with phycoerythrin-conjugated tetramers, anti-CD8-tricolor MAb, and a monoclonal antibody from a panel of fluorescein isothiocyanate-conjugated monoclonal antibodies. Panels included anti-CD57, anti-CD28, anti-CD27, anti-CD45RA, anti-CD45RO, anti-CCR7, and anti-perforin. A, Donor 014; B, donor 004; C, donor 002, showing phenotype of VLEETSVML-specific CD8 þ T cells; D, donor 002, showing phenotype of NLVPMVATV-specific CD8 þ T cells. Tetramer staining is displayed on the Y-axis, and antibody staining is displayed on the X-axis.
total anti-HCMV CTL response [7] , but this view has recently been revised [10] , and the revised view is supported by our data. HLA peptide tetramers visualized HLA-A*0201-restricted IE-1 epitope-specific CD8 þ T cells at high frequencies (as many as 4.25% of CD8 þ T cells) in healthy virus carriers. In a number of cases, the response to the identified IE-1 epitope was shown to exceed that of the published HLA-A*0201 pp65 epitope (NLV). A similar result was reported by Kern et al. [10] in studies of HLA-B*0702-positive donors.
Importantly, the epitope we describe is presented by the most common HLA class I allele, HLA-A*0201, and therefore is applicable to 40% of the population. The majority of HLA-A*0201-positive donors make detectable responses to the pp65 epitope NLV, but some do not, and we have shown that these make a response to VLE. Therefore, the inclusion of this epitope in any potential vaccine could be valuable. In addition, adoptive transfer of CMV-specific T cells to prevent CMV reactivation has been used with pp65-specific CD8 þ T cell clones [4] . The IE-1-specific clones that we generated do not efficiently kill HCMV-infected target cells in vitro unless the cells are treated with IFN-g, which is in agreement with data reported elsewhere [22] . However, recent experiments with murine CMV show that virally infected macrophages are efficiently killed by IE-1-specific CD8 þ T cells [24] , which indicates that IE-1-specific CTL may be more effective in vivo than they appear to be in vitro.
In addition to the VLE epitope (residues 316-324), another peptide from IE-1 was shown to be immunogenic in 1 donor (017). Interestingly, this response was against the YVL epitope (residues 315-323), which is the nonameric peptide that precedes the VLE epitope by 1 aa in the IE-1 protein sequence. We observed very low levels of cross-reactivity in ELISPOT responses against these 2 peptides, which suggests that they are bound to HLA-A*0201 in different conformations. In addition, attempts to stain YVL-specific clones with HLA peptide tetramers were not successful, perhaps because of low-avidity TCR interactions [25] .
HLA peptide tetramer staining of VLE-specific CTL facilitated a detailed analysis of TCR expression and phenotype ex vivo, without requiring prolonged in vitro expansion of antigenspecific T cells. Flow cytometric analyses demonstrated restricted TCRBV use, with just 1 or 2 TCRBV alleles expressed in 3 donors studied. Three of 5 donors used the TCRBV5.1 allele, and DNA sequence analysis showed a common TCR sequence in all donors. Similar examples of conserved TCR use in the recognition of peptide epitopes have been observed in other viral infections [26, 27] . It has been demonstrated that pp65-specific CD8 þ T cells have restricted TCRBV use and, in most cases, consist of a few clones that have undergone extensive expansion in vivo [21] . VLE-specific CTL also appear to be represented by .1 T cell clone, which implies that a similar selection process has occurred, perhaps as a result of repeated challenge by antigen during viral reactivation.
VLE-specific CD8 þ T cells have high CD57 and low CD28 expression, which is typical of CMV-specific memory T cells [14, 28] . The absence of staining for CCR7 and high levels of intracellular perforin also supported the view that these cells were terminally differentiated effector cells [29] . VLE-specific CD8 þ T cells in 2 donors had high levels of CD45RA and intermediate-to-low levels of CD45RO, whereas the distribution of CD45RA þ and CD45RO þ cells in another 2 donors was approximately equal. CD45RA expression is observed on antigenexperienced cells that have reverted from CD45RO expression back to this phenotype [30, 31] . A differentiated phenotype (CD57 þ CD28 2 ) and CD45RA expression are also shown by pp65-specific CD8 þ T cells [14] . Interestingly, in 1 donor, IE-1 (VLE)-and pp65 (NLV)-specific cells were homogeneously low in CD45RA and high in CD45RO. The functional significance of differences in CD45 isoform expression is unclear. It would have been valuable to relate the magnitude and phenotype of the T cell response to measurement of virus load. However, it did not prove to be possible to quantitate virus load in any of the donors studied (data not shown).
These data suggest that both pp65-and IE-1-specific CD8 þ T cells can be driven by high levels of antigen stimulation. The reason HCMV stimulates such high levels of virus-specific CD8 þ T cells is unknown, but this may reflect viral replication in antigenpresenting cells [32] . One study has shown that IE-1 antigen processing and presentation is selectively inhibited by pp65 in HCMV-infected fibroblasts and may be a cause for the low frequencies of IE-1-specific CD8 þ T cells observed in studies that used in vitro restimulation protocols [33] . The significance of this observation in vivo is unclear, because the high frequencies of VLE-specific CD8 þ T cells imply that IE-1-derived peptides can be presented adequately for these cells to be generated. During HCMV reactivation, IE-1 proteins are expressed before pp65, which is not expressed until relatively late in the HCMV life cycle. Because it has been demonstrated that HCMV reactivation occurs intermittently, even in healthy donors, such reactivation may allow for repeated presentation of IE-1-derived peptides and, thus, repeated stimulation of cognate T cells [34, 35] . Although direct presentation of antigen on virally infected cells is probably a major stimulus to expansion of CD8 þ T cells, indirect presentation via uptake of viral protein by dendritic cells is also likely [36] .
In conclusion, we have demonstrated that HCMV-specific CD8 þ T cells against 2 immunodominant proteins derived from HCMV show significant similarities in terms of their frequency, phenotype, and clonality. These data extend the observations that HCMV seropositivity is associated with very strong HCMVspecific CD8 þ T cell immunity and reinforces the concept that IE-1-specific responses can be as high as those against pp65 in certain persons.
